Clinical Trials Logo

Bacillus Anthracis (Anthrax) clinical trials

View clinical trials related to Bacillus Anthracis (Anthrax).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01641991 Completed - Clinical trials for Bacillus Anthracis (Anthrax)

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

Start date: July 2012
Phase: Phase 4
Study type: Interventional

A Phase IV, randomized, multicenter trial to assess the immunogenicity and safety of BioThrax® in varying dose regimens with the primary objective of obtaining information on possible dose-sparing strategies in the event of a major biothreat.

NCT ID: NCT00170469 Completed - Clinical trials for Bacillus Anthracis (Anthrax)

Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.

NCT ID: NCT00138411 Completed - Clinical trials for Bacillus Anthracis (Anthrax)

Monoclonal Antibody for Treatment of Inhalation Anthrax

Start date: October 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics (how long a drug stays in the bloodstream and how high the levels of the drug are at different times) of ETI-204 following intravenous (IV-into a vein) injections, and to evaluate the effects that ETI-204 may have on the pharmacokinetics of oral (by mouth) ciprofloxacin, an antibiotic approved by the U.S. Food and Drug Administration (FDA). ETI-204 is an experimental drug (not approved by the FDA) intended to protect against anthrax (a bacterial infection). Approximately 36 male and female healthy volunteers ages 18 to 50 will be in this study. Participation in this study may last up to eight weeks. Volunteers will have a single IV dose of the ETI-204 study drug or placebo (inactive substance, and some participants will also receive ciprofloxacin. They will stay in the Clinical Pharmacology Unit at least 36 hours after the dose.